AstraZeneca shares rise
AstraZeneca’s shares rise as it addresses China investigation
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company confirmed that its Chinese business is under investigation for alleged unpaid import taxes on certain cancer drugs, including Imfinzi (durvalumab) and Imjudo (tremelimumab).
Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...
A Liberal Democrat peer has accused the government of favouring the south-east of England over Merseyside after AstraZeneca ...
The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.
AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...
AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...
(Reuters) -Strong results from AstraZeneca helped London's blue-chip index notch a record close on Thursday, while a dovish ...
AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...
GlobalData on MSN9h
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trialResearchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
FTSE 100 heavyweight AstraZeneca helped propel the blue-chip index to a record high today. Here's what investors were ...
A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback